356 related articles for article (PubMed ID: 30676661)
21. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
22. Dose-related effects of clozapine and risperidone on the pattern of brain regional serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
Batool F; Hasnat A; Haleem MA; Haleem DJ
Acta Pharm; 2010 Jun; 60(2):129-40. PubMed ID: 21134850
[TBL] [Abstract][Full Text] [Related]
23. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients.
Catafau AM; Penengo MM; Nucci G; Bullich S; Corripio I; Parellada E; García-Ribera C; Gomeni R; Merlo-Pich E;
J Psychopharmacol; 2008 Nov; 22(8):882-94. PubMed ID: 18308793
[TBL] [Abstract][Full Text] [Related]
25. In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.
Loryan I; Melander E; Svensson M; Payan M; König F; Jansson B; Hammarlund-Udenaes M
Mol Psychiatry; 2016 Nov; 21(11):1527-1536. PubMed ID: 26809840
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Matsui-Sakata A; Ohtani H; Sawada Y
Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
[TBL] [Abstract][Full Text] [Related]
27. A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
Kapur S
Mol Psychiatry; 1998 Mar; 3(2):135-40. PubMed ID: 9577837
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
Mukherjee J; Christian BT; Narayanan TK; Shi B; Mantil J
Neuropsychopharmacology; 2001 Oct; 25(4):476-88. PubMed ID: 11557161
[TBL] [Abstract][Full Text] [Related]
29. Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial.
Veselinović T; Scharpenberg M; Heinze M; Cordes J; Mühlbauer B; Juckel G; Rüther E; Paulzen M; Haen E; Hiemke C; Timm J; Gründer G;
J Clin Psychopharmacol; 2019; 39(6):550-560. PubMed ID: 31688449
[TBL] [Abstract][Full Text] [Related]
30. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
31. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
32. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
33. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
34. Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles.
Selvaggi P; Hawkins PCT; Dipasquale O; Rizzo G; Bertolino A; Dukart J; Sambataro F; Pergola G; Williams SCR; Turkheimer F; Zelaya F; Veronese M; Mehta MA
Neuroimage; 2019 Mar; 188():774-784. PubMed ID: 30553916
[TBL] [Abstract][Full Text] [Related]
35. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?
Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Kodaka F; Okumura M; Otsuka T; Suhara T
J Neurosci; 2009 Oct; 29(43):13730-4. PubMed ID: 19864585
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2015 Jan; 55(1):93-103. PubMed ID: 25043337
[TBL] [Abstract][Full Text] [Related]
38. Saturation of striatal D(2) dopamine receptors by clozapine.
Nyberg S; Chou YH; Halldin C
Int J Neuropsychopharmacol; 2002 Mar; 5(1):11-6. PubMed ID: 12057028
[TBL] [Abstract][Full Text] [Related]
39. Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling.
van den Brink WJ; Wong YC; Gülave B; van der Graaf PH; de Lange EC
AAPS J; 2017 Jan; 19(1):274-285. PubMed ID: 27785749
[TBL] [Abstract][Full Text] [Related]
40. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
